CALGARY,
AB, Dec. 11, 2024 /CNW/ - Nanalysis
Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA:
1N1), a leader in portable NMR instruments and MRI technology
for industrial and research applications announces results of study
by the United States Pharmacopeia (USP) concluding that benchtop
NMR is efficacious for quality control of active pharmaceutical
ingredients (API).
"In the not-too-distant future, we expect that benchtop NMR will
become an important tool in the multi-billion-dollar market for
quality control in the pharmaceutical industry," said Sean
Krakiwsky, Founder and CEO of Nanalysis. "NMR has long been a
gold standard for testing at a molecular level. Due to the size and
requirements of larger legacy NMR instruments, they were not
practical for use in many environments, like larger scale
production/manufacturing facilities. Our novel benchtop NMR
products provide high quality data with reliability and convenience
that, due to their form factor, work well in these
applications."
"Our scientific and product teams are doing great work
establishing regulatory tailwinds, reducing expertise required to
generate and process data, increasing automation and establishing
partnerships in this area," continued Mr.
Krakiwsky.
Ben Shapiro, Digital Product
Development Director at USP says, "USP has a long history of
developing quality standards for prescription drugs,
over-the-counter drugs, and veterinary medicines to ensure the
highest level of quality. The release of USP-ID reflects our
commitment to leveraging innovative technologies to automate and
normalize NMR data, supporting modernization and digitalization in
pharmaceutical quality control. Advances such as benchtop nuclear
magnetic resonance (NMR) spectroscopy help make testing methods,
like qNMR, more accessible and scalable."
Dr. Susanne D. Riegel, Nanalysis
VP Marketing & NMR Product Manager says, "We have been
working closely with USP as they look to modernize their monographs
and methodology throughout QA in the pharmaceutical industry.
While, not as established as other techniques, such as liquid
chromatography, benchtop NMR can have the following benefits:
- faster measurements
- reduction in harmful and expensive solvent consumption
- Simple sample preparation
- can be run without calibration
- Non-destructive, and non-targeted, increasing reliability of
measurements
"The use of an automated analysis method, like USP-ID, reduces
the barrier to entry for benchtop NMR into pharma/biotech QC, and
helps establish the value proposition to do so. The market for
pharmaceutical quality control is multi-billion per year globally,
and we expect data regulatory requirements to tighten, driven by
demand for more consistent safer pharmaceuticals. Now that NMR has
become miniaturized, it will become a critical technique in this
market, due to its clear advantages of accessibility, affordability
and automatability.
"Our company continues to provide innovative hardware and
software solutions. By establishing great working
relationships with organizations, such as USP, over the next
several years, we expect to submit many benchtop NMR methods to USP
for their acceptance, which will in turn be a growth driver for
QA/QC in the pharmaceutical industry globally as we work also with
other pharmacopeia jurisdictions, such as Europe and Japan."
Click on this link for full access to the USP publication:
https://go.usp.org/WhitePaperBenchtopNMR
About Nanalysis Scientific Corp. (TSXV:
NSCI, OTCQX: NSCIF, FRA:1N1)
Nanalysis Scientific Corp. in operates two primary business
segments: Scientific Equipment and Security Services. Within its
Scientific Equipment business is what the Company terms "MRI and
NMR for industry". The Company develops and manufactures portable
Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for
laboratory and industrial markets. The NMReady-60™ was the first
full-feature portable NMR spectrometer in a single compact
enclosure requiring no liquid helium or any other cryogens. The
Company has followed-up that initial offering with new products and
continues to have a strong innovation pipeline. In 2020, the
Company announced the launch of its 100MHz device, the most
powerful and most advanced commercial compact NMR device ever
brought to market.
The Company's devices are used in many industries (oil and gas,
chemical, mining, pharma, biotech, flavor and fragrances,
agrochemicals, law enforcement, and more) as well as numerous
government and university research labs around the world. The
Company is working to expand into new global market opportunities
independently and with partners. With its partners, the
Company provides scientific equipment sales and maintenance
services globally.
In 2022 the Company was awarded a five-year, $160 million contract to provide maintenance
services for passenger screening equipment in Canadian
airports. This has resulted in expansion of the Company's
Security Services business. The Company is providing airport
security equipment maintenance services in each province and
territory of Canada. In addition, the Company provides
commercial security equipment installation and maintenance services
to a variety of customers in North America.
About USP
USP is an independent scientific organization that collaborates
with the world's top experts in health and science to develop
quality resources and standards for medicines, dietary supplements
and food ingredients. This includes actively collaborating with
academic research centers, industry, and regulators to help with
the adoption and implementation of advanced manufacturing
technologies. Through our resources, standards, advocacy and
education, USP helps increase the availability of quality
medicines, supplements and foods for billions of people worldwide.
For more information, visit: www.usp.org.
The usage of Nanalysis NMR equipment with USP-ID in the study
does not imply approval, endorsement, or certification by USP of
Nanalysis products, nor does it imply that Nanalysis products are
necessarily the best available product for the purpose or that any
other brand or product was judged to be unsatisfactory or
inadequate. As a standard setting organization, USP avoids
conflicts of interest that interfere or appear to interfere with
its impartiality and objectivity.
Notice regarding Forward Looking Statements and Legal
Disclaimer
This news release contains certain "forward-looking statements"
within the meaning of such statements under applicable securities
law. Forward-looking statements are frequently characterized by
words such as "anticipates", "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed", "positioned" and other similar
words, or statements that certain events or conditions "may" or
"will" occur. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nanalysis-and-the-united-states-pharmacopeia-usp-co-publish-study-demonstrating-efficacy-of-benchtop-nmr-for-quality-control-302328659.html
SOURCE Nanalysis Scientific Corp.
